Stereotactic Radiosurgery of Intracranial Chordomas, Chondrosarcomas, and Glomus Tumors

Hideyuki Kano, MD, PhD*, L. Dade Lunsford, MD

INTRODUCTION

Chordomas are slowly-growing, locally aggressive tumors that arise from embryonic remnants of the notochord and show a dural epithelial-mesenchymal differentiation.1 They arise from the sacrococcygeal region in 50% to 60% of patients, from the skull base region in 25% to 35%, and from the vertebrae in 15%.2 The natural history of untreated clival chordomas is dismal, with a mean survival of less than 1 year.3 Neurologic deficits tend to vary based on the location of the tumor. An abducens nerve deficit causing diplopia is the most frequent presenting sign.4,5

CHORDOMAS

Therapeutic Options

Aggressive initial management, beginning with radical resection when possible and followed by fractionated radiation therapy or radiosurgery, improves overall outcome.6 Earlier recognition of these tumors7–10 facilitates aggressive therapy. Complete resection without significant morbidity is rarely feasible because these tumors tend to encase critical vessels and cranial nerves, or adhere to the brainstem.11–15 The recurrence rate, even after virtually complete resection, remains high.16,17 Recurrent tumors are even more challenging for
extirpation. Most patients undergo adjuvant radiation therapy to reduce the risk of tumor recurrence. Chordomas are considered radioresistant tumors that require total fractionated radiation therapy doses in excess of 60 Gy to reduce recurrence rates. Fractionated stereotactic radiation therapy using high-energy photons or fractionated charged particle radiation (most often protons) are the 2 most commonly administered forms of radiation for chordomas. Prior reports comparing results of photon irradiation with proton beam therapy rarely take into account the more recent evolution of photon-based treatments in which energies are higher, and targeting and delivery methods have been enhanced. Regardless of the radiation modality, the maximum dose of radiation that can be safely delivered is limited by the tolerance of the surrounding critical cranial nerve, brainstem, or temporal lobe structures.

Based on the principle of Bragg peak deposition of energy that reduces exit dose, fractionated, charged-particle radiation delivered by protons or carbon ions is thought by some to deliver a more radiobiologically potent dose to the tumor. The Bragg peak effect results in a rapid energy deposition at the target volume, with a steep dose drop-off beyond the target volume treated. With proton beam radiation therapy, doses greater than 70 cobalt gray equivalent (CGE) are prescribed. CGE is an empiric measure of estimated radiation effect obtained through multiplying the conventional photon radiation dose in Gy by 1.2, a value that has been postulated but unproven to be the potential radiobiological advantage of proton Bragg peak radiation therapy. Published data indicate that experienced centers may achieve local tumor control rates of 67% to 88% at 3 years, 46% to 73% at 5 years, and 54% at 10 years. The overall survival rates are 67% to 81% at 5 years and 54% at 10 years. These results are often interpreted as superior to those reported for chordomas treated by older fractionated photon radiation therapy techniques before the era of intensity-modulated radiation therapy (IMRT). Using carbon ion therapy, Castro and colleagues treated 53 patients with doses of 60 to 80 CGE. They reported 5-year local tumor control and overall survival rates of 63% and 75%, respectively. Schulz-Ertner and colleagues reported that 96 patients with chordoma who underwent carbon ion fractionated radiation therapy showed 5-year local tumor control and overall survival rates of 70% and 88.5%, respectively. Late toxicity consisted of optic nerve neuropathy Radiation Therapy Oncology Group (RTOG)/European Organisation for Research and Treatment of Cancer (EORTC) grade 3 in 4.1% of the patients. Minor temporal lobe injury (RTOG/EORTC grade 1–2) occurred in 7.2% of the patients.

Noel and colleagues reported the results of combined fractionated photon and proton radiation therapy in 90 patients with either chordomas (n = 64) or chondrosarcomas (n = 26) of the skull base. The tumors were treated to a median total dose of 67 CGE (range, 22–70 CGE). Photons represented two-thirds of the total delivered dose, and protons represented one-third. At a median follow-up of 34 months, local tumor control was achieved in 65 patients (72%). All 90 patients developed immediate adverse radiation effects, usually mild. However, 6% reported late grade III or IV radiation toxicities, including cranial nerve deficits and visual loss. Proton fractionated radiation therapy remains a relatively expensive strategy that is available in a limited but increasing number of facilities in the United States and abroad.

### Clinical Outcomes of Stereotactic Radiosurgery

Stereotactic radiosurgery (SRS) is a surgical technique designed to achieve a greater radiobiological effect than conventional 3-dimensional conformal radiation therapy or IMRT. SRS has been used as a minimally invasive primary or adjuvant management option for chordomas (Table 1). SRS using the Leksell Gamma Knife (Elekta Inc, Norcross, GA) is a surgical procedure that delivers cross-fired photon radiation generated from the decay of cobalt 60 sources in a single wheels-in-to-wheels-out procedure. Using linear accelerator technologies, such as the Accuray CyberKnife (Accuray, Sunnyvale, CA), SRS may be delivered in up to 5 treatment sessions. Delivery of such highly focused radiation in 1 to 5 sessions significantly increases the radiobiological effect of SRS compared with conventional fractionated radiation therapy. Using methods to evaluate radiobiological effects, the center of the tumor may receive a radiobiological effect 4 times of what can be safely delivered using conventional fractionated radiation or IMRT. SRS seems especially valuable for the treatment of relatively small residual or recurrent chordomas after prior surgical resection. SRS has been frequently added as a radiobiological boost to conventional fractionated radiation therapy. Krishnan and colleagues treated 25 patients with cranial base chordoma with SRS using a median tumor margin dose of 15 Gy. The 5-year treated tumor control rate was 52% at a median follow-up of 4.5 years. Hasegawa and colleagues performed SRS on 27 patients with chordoma with median tumor...
margin doses of 14 Gy. They noted 5-year local tumor control and overall survival rates of 42% and 80%, respectively, at a median follow-up of 59 months. In their series, only tumor volumes of less than 20 cm³ were significantly associated with a longer progression-free survival (PFS). Liu and colleagues³⁵ reported on 28 patients with residual skull base chordoma who underwent SRS with median margin dose of 12.7 Gy. The average follow-up was 28 months and the mean tumor volume was 11.4 ± 7.4 cm³. The 5-year overall survival and in-field tumor control rates were 75.8% and 21.4%, respectively. No serious adverse radiation effects (AREs) were reported.

Kano and colleagues³⁶ reported that 6 participating centers of the North American Gamma Knife Consortium identified 71 patients who underwent Gamma Knife SRS for chordomas. The median patient age was 45 years (range, 7–80 years). The median SRS target volume was 7.1 cm³ (range, 0.9–109.0 cm³) and the median tumor margin dose was 15.0 Gy (range, 9–25 Gy). At a median follow-up of 5 years after SRS (range, 0.6–14.0 years), 23 patients died because of tumor progression. The 5-year actuarial overall survival after SRS for the entire group was 80%. Tumor control was higher (93%) in patients who had not undergone prior fractionated radiation therapy (n = 50). Tumor control was reduced to 43% in patients who underwent prior fractionated radiation therapy (n = 21). Factors associated with longer patient survival included younger age, longer interval between initial diagnosis and SRS, no prior radiation therapy, fewer than 2 cranial nerve deficits, and smaller total tumor volumes. The 5-year treated tumor control rates after SRS for the entire group was 66% (69% for the no prior fractionated radiation therapy group and 62% for the prior fractionated radiation therapy group). Significant factors associated with reduced tumor control included older age, recurrent tumors, prior fractionated radiation therapy, and larger tumor volumes. Of 57 patients with pretreatment neurologic deficits, 17 (30%) experienced neurologic improvement. Of 65

### Table 1
Studies and patient characteristics in published series of chordoma treated with SRS

<table>
<thead>
<tr>
<th>Reference</th>
<th>N</th>
<th>Radiation</th>
<th>Median Margin Dose (range)</th>
<th>Tumor Volume</th>
<th>% Local Control</th>
<th>% Survival</th>
<th>Median Follow-up (mo)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Krishnan et al,³³ 2005</td>
<td>19</td>
<td>SRS ± RT</td>
<td>15.0 Gy (10.0–20.0 Gy) ± 50.4 Gy (45.0–54.0 Gy)</td>
<td>14.4 cm³</td>
<td>4 y: 55</td>
<td>NA</td>
<td>58</td>
</tr>
<tr>
<td>Hasegawa et al,³² 2007</td>
<td>27</td>
<td>SRS</td>
<td>14 Gy (9–20 Gy)</td>
<td>19.7 cm³</td>
<td>5 y: 72</td>
<td>10 y: 72</td>
<td>5 y: 84</td>
</tr>
<tr>
<td>Liu et al,³⁵ 2008</td>
<td>31</td>
<td>SRS</td>
<td>12.7 Gy (10.0–16.0 Gy)</td>
<td>11.4 cm³</td>
<td>3 y: 64</td>
<td>5 y: 21</td>
<td>3 y: 91</td>
</tr>
<tr>
<td>Kano et al,³⁶ 2011</td>
<td>71</td>
<td>SRS ± RT</td>
<td>15 Gy (9–25 Gy)</td>
<td>7.1 cm³</td>
<td>5 y: 79</td>
<td>5 y: 66</td>
<td>5 y: 80</td>
</tr>
</tbody>
</table>

**Abbreviations:** NA, not available; RT, fractionated radiation therapy.
patients with clinical follow-up, 31 (48%) remained stable, but 17 (26%) eventually had deterioration in neurologic function. Deterioration was related to treated tumor progression in 8 patients, adjacent tumor progression in 3, treatment-associated AREs in 4, and both treated tumor progression and AREs in 2.

Summary

Maximal safe resection should be the primary initial treatment for chordomas. After recovery from surgery, fractionated Bragg peak proton radiation therapy at an experienced center remains an option for the additional treatment of chordomas. Careful planning and reduction of dose delivered to adjacent critical structures are critical components, whether using particle beam or modern fractionated photon radiation techniques. Long-term evaluation of neurocognitive effects are warranted because of the relatively higher dose that may be delivered via the entrance pathway within the temporal lobes. SRS after surgical resection also provides a reasonable benefit-to-risk profile for small- to medium-sized chordomas. SRS is an important option for patients with recurrent tumors that failed to respond to initial surgical resection. Current data suggest that it might well supplant radiation therapy as the next best option for residual smaller-volume tumors.

CHONDROSARCOMA

Chondrosarcomas are relatively slow-growing, locally invasive tumors that usually do not metastasize until very late in the natural history. Cranial chondrosarcomas originate from primitive mesenchymal cells within the cartilaginous matrix of the skull base. The imaging features and clinical presentations of patients harboring either chordomas or chondrosarcomas are similar. Chordomas have a tendency to cause brainstem compression because they arise from the clivus, whereas chondrosarcomas tend to affect the lower cranial nerves because they frequently originate from the occipitotemporal bone synchondrosis. The most common presenting symptom of chondrosarcoma is diplopia, secondary to an abducens nerve palsy. Using imaging alone to distinguish chondrosarcomas from chordomas is often difficult but important, because the prognosis is generally considered better for chondrosarcomas.

Therapeutic Options

Chondrosarcomas are rarely completely resectable, and additional management options must be considered for residual tumors. Gay and colleagues reported a 90% overall survival at 5 years for 14 patients who underwent either skull base surgery or surgery followed by radiation therapy. Crockard and colleagues reported a 93% 5-year survival rate for 17 patients who underwent surgery alone. Bloch and colleagues found a recurrence rate of 44% in patients who underwent surgical resection alone, compared with 9% in patients who had surgery followed by radiation therapy. A recent review of the literature described 560 patients with intracranial chondrosarcomas, which were associated with a 5-year mortality rate of 11.5% and a median survival of 24 months. No association was seen between the rate of recurrence and the histologic grade of the tumor. In a study of 8 patients with chondrosarcomas and 8 with chordomas of the skull base who underwent proton radiation therapy, Fuji and colleagues reported a local control rate at 3 years of 86% and a median follow-up of 42 months. Other studies using proton radiation therapy have also reported overall survival and local tumor control rates at 5 years to be greater than 90%.

Clinical Outcomes of SRS

Relatively few data exist to define the use of SRS in the multimodal management of chondrosarcoma (Fig. 2, Table 2). SRS has been shown to result in less toxicity to surrounding structures and have fewer complications than fractionated radiation therapy in the management of chondrosarcomas. Koga and colleagues reported the results of 4 patients who had surgical resection followed by SRS at a median follow-up of 99 months. Three of the patients, who received margin doses of 15, 16, and 20 Gy, had no change in tumor size during follow-up. One patient who received a lower tumor margin dose of 12 Gy developed tumor recurrence 100 months after SRS. Hasegawa and colleagues studied 30 patients with chordomas and 7 patients with chondrosarcomas who underwent SRS. The 5-year PFS rate in patients with low-grade chondrosarcomas was 76%. A tumor volume of less than 20 mL significantly improved PFS. Krishnan and colleagues reported that 4 patients with chondrosarcomas who underwent SRS had tumor control at 5 years.

Iyer and colleagues studied 22 patients who underwent Gamma Knife SRS for residual or recurrent intracranial chondrosarcomas. Overall patient survival rates after SRS were 95%, 70%, and 56% at 1, 5, and 10 years, respectively. Factors associated with longer survival after SRS included a shorter interval (<6 months) between...
diagnosis and SRS, age older than 40 years, and either a single or no prior resection. Treated tumor control rates were 91% at 1 year, 72% at 5 years, and 54% at 10 years. Factors associated with longer PFS after SRS included patient age older than 40 years and no prior radiation therapy.

**Summary**

The ability to achieve tumor growth control of chondrosarcomas is likely to be enhanced by earlier recognition and the application of multimodal treatment in appropriate patients. Maximal safe resection should be the primary initial management of chondrosarcomas. Gamma Knife radiosurgery is a reasonable therapeutic option as an adjuvant treatment after resection in selected patients with chondrosarcomas.

**GLOMUS JUGULARE TUMORS**

Glomus jugulare tumors are rare, highly vascularized tumors that arise from the paraganglionic structures of the glossopharyngeal and vagal nerves. Because of their highly vascular nature and generally inaccessible anatomic location, surgical resection is often challenging. The ideal treatment for patients with a glomus tumor remains controversial. Treatment options include surgical resection, endovascular embolization, fractionated radiation therapy, and SRS alone or in combination.

**Clinical Outcomes of SRS**

Liscak and colleagues reported on 52 patients with glomus jugulare tumors treated with SRS (Fig. 3, Table 3); 24 had prior surgical resection, 14 had prior embolization, and 5 had prior RT. The median tumor volume was 5.7 cm³ (range, 0.5–27.0 cm³) and median margin dose was 16.5 Gy (range, 10–30 Gy). All patients had tumor control at a median of 24 months. The neurologic symptom control rate was 96%. Ivan and

---

**Table 2**

Studies and patient characteristics in published series of chondrosarcoma treated with SRS

<table>
<thead>
<tr>
<th>Reference</th>
<th>N</th>
<th>Radiation</th>
<th>Median Margin Dose</th>
<th>Tumor Volume</th>
<th>% Local Control</th>
<th>% Survival</th>
<th>Median Follow-up (mo)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Krishnan et al,33</td>
<td>4</td>
<td>SRS</td>
<td>15 Gy</td>
<td>14.4 cm³</td>
<td>5 y: 100</td>
<td>NA</td>
<td>58</td>
</tr>
<tr>
<td>Hasegawa et al,32</td>
<td>7</td>
<td>SRS</td>
<td>14 Gy</td>
<td>19.7 cm³</td>
<td>5 y: 76</td>
<td>10 y: 90</td>
<td>59</td>
</tr>
<tr>
<td>Cho et al,54,2008</td>
<td>11</td>
<td>SRS ± RT</td>
<td>12.7 Gy ± 58.2 Gy</td>
<td>3.7 cm³</td>
<td>5 y: 89</td>
<td>10 y: 80</td>
<td>56</td>
</tr>
<tr>
<td>Koga et al,48,2010</td>
<td>4</td>
<td>SRS</td>
<td>15.6 Gy</td>
<td>NA</td>
<td>5 y: 100</td>
<td>10 y: 100</td>
<td>65</td>
</tr>
<tr>
<td>Iyer et al,49,2012</td>
<td>22</td>
<td>SRS ± RT</td>
<td>15 Gy</td>
<td>8.0 cm³</td>
<td>5 y: 72</td>
<td>10 y: 70</td>
<td>60</td>
</tr>
</tbody>
</table>

*Abbreviations: NA, not available; RT, fractionated radiation therapy.*
colleagues reported a meta-analysis of tumor control and morbidity for patients with glomus jugulare tumors. They identified 869 patients with glomus jugulare tumors from 46 publications. Patients underwent gross total resection alone had a tumor control rate of 86% at a mean follow-up of 88 months. Patients who underwent subtotal resection followed by SRS had a tumor control rate of 71% at a mean follow-up of 96 months. Patients who underwent SRS alone had a tumor control rate of 95% at a mean follow-up of 71 months. Patients who underwent gross total resection sustained worse rates of cranial nerve (CN) deficits with regard to CN IX–XI than those who underwent SRS alone.

In a meta-analysis of 19 studies involving 335 patients with glomus jugulare tumors who underwent SRS, Guss and colleagues reported that 97% of patients experienced tumor control and 95% experienced clinical control. Sheehan and colleagues performed a large retrospective multicenter study of Gamma Knife SRS for glomus jugular tumors, involving 134 procedures in 132 patients, with a median follow-up of 50.5 months. Prior resection was performed in 51 patients, and prior fractionated radiation therapy was performed in 6 patients. The median tumor volume was 5.5 cm$^3$ (range, 0.6–58.6 cm$^3$). The median margin dose was 15 Gy (10–18 Gy). The 5-year tumor control rate was 88% after SRS. Absence of trigeminal nerve dysfunction at the time of radiosurgery and higher number of isocenters were significantly associated with PFS. Patients showing new or progressive cranial nerve deficits were also likely to show tumor progression. Pulsatile tinnitus improved in 49% of patients who reported it at presentation. New or progressive cranial nerve deficits were noted in 15% of patients, and improvement in preexisting cranial nerve deficits was observed in 11% of patients. No patient died as a result of tumor progression.

![Fig. 3. T1-weighted contrast-enhanced axial (upper), coronal (middle), and sagittal (lower) magnetic resonance imaging scan of glomus jugulare tumor, showing the stereotactic radiosurgery target with a margin dose of 12 Gy.](image)

<table>
<thead>
<tr>
<th>Reference</th>
<th>N</th>
<th>Radiation</th>
<th>Median Margin Dose</th>
<th>Tumor Volume</th>
<th>% Local Control</th>
<th>% Symptom Control</th>
<th>Median Follow-up (mo)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liscak et al, 1999</td>
<td>66</td>
<td>SRS ± RT</td>
<td>16.5 Gy</td>
<td>5.7 cm$^3$</td>
<td>100</td>
<td>96</td>
<td>24</td>
</tr>
<tr>
<td>Pollock et al, 2004</td>
<td>42</td>
<td>SRS</td>
<td>14.9 Gy</td>
<td>19.7 cm$^3$</td>
<td>97</td>
<td>NA</td>
<td>44</td>
</tr>
<tr>
<td>Gerosa et al, 2006</td>
<td>20</td>
<td>SRS</td>
<td>17.5 Gy</td>
<td>7 cm$^3$</td>
<td>100</td>
<td>90</td>
<td>50</td>
</tr>
<tr>
<td>Genc et al, 2010</td>
<td>18</td>
<td>SRS</td>
<td>15.6 Gy</td>
<td>5.5 cm$^3$</td>
<td>94</td>
<td>94</td>
<td>53</td>
</tr>
<tr>
<td>Sheehan et al, 2012</td>
<td>134</td>
<td>SRS ± RT</td>
<td>15 Gy</td>
<td>5.5 cm$^3$</td>
<td>92.7</td>
<td>85</td>
<td>50.5</td>
</tr>
</tbody>
</table>

Abbreviations: NA, not available; RT, fractionated radiation therapy.
Summary

SRS affords a high rate of local tumor control and a low risk of neurologic complications for patients with glomus jugulare tumors. SRS can be used as an up-front treatment or as an additional treatment for those with recurrent or residual tumor after surgical resection.

REFERENCES